Testing vaccines and biologics against dangerous infectious diseases in non-human primates
Official title: Task V02: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates
Funded at Battelle Centers/pub Hlth Res & Evaluatn · NIH-10636609 · Data updated 2026-11-12
This study is testing new vaccines and treatments to help protect against serious infections like the Marburg virus, using non-human primates to see how well they work before they can be given to people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Battelle Centers/pub Hlth Res & Evaluatn NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | August 1, 2019 |
| Project end | December 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $134,146 |
| NIH project number | 272201800013I-P00006-759301900131-1 |
| Project ID | NIH-10636609 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals at high risk for exposure to BSL-4 pathogens or those living in areas where these diseases are prevalent.
✕Less likely to help
Patients who are not at risk for BSL-4 pathogens or those with existing immunity to the targeted diseases may not receive direct benefits from this research.
What this research studies
This research focuses on evaluating the effectiveness and safety of new vaccines and biologics designed to combat severe infectious diseases, specifically targeting BSL-4 pathogens like the Marburg virus. The study involves non-human primates to assess how well these medical countermeasures work before they are considered for human trials. By conducting early feasibility studies and preparing necessary applications for regulatory approval, the research aims to streamline the development of these critical health interventions.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines and treatments for deadly infectious diseases, improving public health and safety.
How similar studies have gone: Previous research has shown success in developing vaccines for other infectious diseases using similar methodologies, indicating a promising potential for this approach.
Where this research is happening
-
Battelle Centers/pub Hlth Res & Evaluatn
Columbus, United States Active
Researchers
- Principal investigator: Rudge, Thomas — Battelle Centers/pub Hlth Res & Evaluatn
- Study coordinator: Rudge, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.